Zivo Bioscience Inc (ZIVO) - Total Assets
Based on the latest financial reports, Zivo Bioscience Inc (ZIVO) holds total assets worth $559.45K USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Zivo Bioscience Inc shareholders equity for net asset value and shareholders' equity analysis.
Zivo Bioscience Inc - Total Assets Trend (2003–2024)
This chart illustrates how Zivo Bioscience Inc's total assets have evolved over time, based on quarterly financial data.
Zivo Bioscience Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Zivo Bioscience Inc's total assets of $559.45K consist of 99.5% current assets and 0.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 93.9% |
| Accounts Receivable | $2.21K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2003–2024)
This chart illustrates how Zivo Bioscience Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Zivo Bioscience Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zivo Bioscience Inc's current assets represent 99.5% of total assets in 2024, a decrease from 100.0% in 2003.
- Cash Position: Cash and equivalents constituted 93.9% of total assets in 2024, up from 9.1% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
Zivo Bioscience Inc Competitors by Total Assets
Key competitors of Zivo Bioscience Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Zivo Bioscience Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.08 | 0.17 | 0.01 |
| Quick Ratio | 0.08 | 0.17 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-3.33 Million | $-2.14 Million | $-11.23 Million |
Zivo Bioscience Inc - Advanced Valuation Insights
This section examines the relationship between Zivo Bioscience Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 20.76 |
| Latest Market Cap to Assets Ratio | 8.52 |
| Asset Growth Rate (YoY) | 195.7% |
| Total Assets | $1.64 Million |
| Market Capitalization | $14.00 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Zivo Bioscience Inc's assets at a significant premium (8.52x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Zivo Bioscience Inc's assets grew by 195.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Zivo Bioscience Inc (2003–2024)
The table below shows the annual total assets of Zivo Bioscience Inc from 2003 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.64 Million | +195.68% |
| 2023-12-31 | $555.72K | -73.82% |
| 2022-12-31 | $2.12 Million | -76.39% |
| 2021-12-31 | $8.99 Million | +3983.12% |
| 2020-12-31 | $220.18K | -40.39% |
| 2019-12-31 | $369.39K | -10.23% |
| 2018-12-31 | $411.51K | -90.23% |
| 2017-12-31 | $4.21 Million | +471.02% |
| 2016-12-31 | $737.29K | +914.44% |
| 2015-12-31 | $72.68K | -28.65% |
| 2014-12-31 | $101.86K | -95.32% |
| 2013-12-31 | $2.17 Million | +829.22% |
| 2012-12-31 | $234.00K | -49.51% |
| 2011-12-31 | $463.49K | +36.35% |
| 2010-12-31 | $339.92K | -15.40% |
| 2009-12-31 | $401.80K | -7.66% |
| 2008-12-31 | $435.14K | +58.32% |
| 2007-12-31 | $274.85K | -14.62% |
| 2006-12-31 | $321.92K | -51.22% |
| 2005-12-31 | $659.94K | +1142.03% |
| 2004-12-31 | $53.13K | +439.65% |
| 2003-12-31 | $9.85K | -- |
About Zivo Bioscience Inc
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically act… Read more